Body Shortcuts Side Menu Shortcuts Shortcuts to Large Menu

Notice

2022 KOICA INNOPORT INNO-Lab B (Beginner) Program

Writer Strategic Planning & Relations Date Created 2022.03.21 Hits697

Dear Students,

 

We would like to share valuable program information from KOICA Innoport. KOICA Innoport nurtures young talents and prospective/early entrepreneurs who strive to solve global developmental issues. One of the 2022 Innoport programs, INNO-Lab B (Beginner) is an enrichment program for prospective entrepreneurs in developing countries that will be held from April 2022. We highly endorse this opportunity for all young prospective entrepreneurs who want to start a business in developing countries. All courses of this program will be conducted online in Korean. However, English communication will be required for the team matched with local experts. 

 

image.png

 

  • Program Schedule: Tuesday, April 26 - Tuesday, June 21 / every Tuesday / 14:00 - 17:00
  • Target
    • Preliminary start-up team with local start-up ideas in developing countries
    • Non-corporate team (individual entrepreneurs can apply) 
    • No. of team members should be between 1 and 4 (regardless of nationality but fluency in Korean is required) 
  • Awards (3 teams)
    • 1st place: KRW 5,000,000, 2 seats in KOICA INNOPORT (co-working space), crowd-funding opportunity
    • 2nd place: KRW 2,000,000, 1 seat in KOICA INNOPORT (co-working space), crowd-funding opportunity
    • 3rd place: KRW 1,000,000, crowd-funding opportunity 
  • Benefits
    • Business modeling training and 1:1 coaching by team for prospective entrepreneurs for advancement and commercialization into developing countries will be provided for 9 Weeks
    • Matching local experts (INNO-Partners) by team to identify local markets in developing countries and to test local MVPs  
  • How to Apply: Submit a 2022 INNO-Lab B Registration Form by Monday, April 11, 11:59pm
  • For Inquiry: Phone: 070-8691-3021 / Email: info@innoport.co.kr
이노랩-B-포스터-수정본.png

 

Best, 

 

SUNY Korea CDC